🏅 FDA Orphan Designation
Palsonify
paltusotine
Manufacturer: Crinetics Pharmaceuticals, Inc.
Indicated for:
AcromegalyOrphan
FDA-Approved Indications (1)
AcromegalyOrphan Designation
treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option
Indications & Usage
1 INDICATIONS AND USAGE PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option ( 1 ).
💙 Support Programs
View all →Palsonify
Crinetics Pharmaceuticals, Inc.
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.